The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
New antibiotics for bad bugs: where are we?
Open accessAbstract
Bacterial resistance to antibiotics is growing up day by day in both community and hospital setting, with a significant impact on the mortality and morbidity rates and the financial burden that is associated. In the last two decades multi drug resistant microorganisms (both hospital- and community-acquired) challenged the scientific groups into developing new antimicrobial compounds that can provide safety in use according to the new regulation, good efficacy patterns, and low resistance profile. In this review we made an evaluation of present data regarding the new classes and the new molecules from already existing classes of antibiotics and the ongoing trends in antimicrobial development. Infectious Diseases Society of America (IDSA) supported a proGram, called "the '10 × ´20' initiative", to develop ten new systemic antibacterial drugs within 2020. The microorganisms mainly involved in the resistance process, so called the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and enterobacteriaceae) were the main targets. In the era of antimicrobial resistance the new antimicrobial agents like fifth generation cephalosporins, carbapenems, monobactams, β-lactamases inhibitors, aminoglycosides, quinolones, oxazolidones, glycopeptides, and tetracyclines active against Gram-positive pathogens, like vancomycin-resistant S. aureus (VRSA) and MRSA, penicillin-resistant streptococci, and vancomycin resistant Enterococcus (VRE) but also against highly resistant Gram-negative organisms are more than welcome. Of these compounds some are already approved by official agencies, some are still in study, but the need of new antibiotics still does not cover the increasing prevalence of antibiotic-resistant bacterial infections. Therefore the management of antimicrobial resistance should also include fostering coordinated actions by all stakeholders, creating policy guidance, support for surveillance and technical assistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
Carbapenems: Past, Present, and Future
Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-11 · Cited by 1,502
Clinical relevance of the ESKAPE pathogens
Pendleton, J. N., Gorman, S. P., & Gilmore, B. F. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.12 · Cited by 1,423
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli
Giske, C. G., Monnet, D. L., Cars, O., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01169-07 · Cited by 610
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
The crisis of no new antibiotics—what is the way forward?
Piddock, L. J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70316-4 · Cited by 500
Prokocimer, P., De Anda, C., Fang, E., Mehra, P., & Das, A. (2013) · JAMA · doi:10.1001/jama.2013.241 · Cited by 361
Cited by
Methods for the detection and identification of pathogenic bacteria: past, present, and future
Váradi, L., Luo, J. L., Hibbs, D. E., Perry, J. D., Anderson, R. J., Orenga, S., & Groundwater, P. W. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00693k · Cited by 561
Mechanism of Antimicrobial Peptides: Antimicrobial, Anti-Inflammatory and Antibiofilm Activities
Luo, Y., & Song, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111401 · Cited by 559
Chassagne, F., Samarakoon, T., Porras, G., Lyles, J. T., Dettweiler, M., Marquez, L., Salam, A. M., Shabih, S., Farrokhi, D. R., & Quave, C. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.586548 · Cited by 292
Nguyen, M., & Joshi, S. G. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15130 · Cited by 259
Characterization of microbial siderophores by mass spectrometry
Pluháček, T., Lemr, K., Ghosh, D., Milde, D., Novák, J., & Havlíček, V. (2016) · Mass Spectrometry Reviews · doi:10.1002/mas.21461 · Cited by 74
Metadata
- Authors
- Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A.
- Venue
- Annals of Clinical Microbiology and Antimicrobials
- Published
- 2013
- Volume
- 12
- Issue
- 1
- Pages
- 22
- ISSN
- 1476-0711 (ISSN-L)
- OpenAlex
- W2105794879
- Cited by
- 403
- References
- 63
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New antibiotics for bad bugs: where are we? https://app.cochat.ai/papers/10.1186/1476-0711-12-22
- The paper
- Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A. (2013). New antibiotics for bad bugs: where are we? Annals of Clinical Microbiology and Antimicrobials. https://doi.org/10.1186/1476-0711-12-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
